Pfizer Assesses Cancer Risk from Amoxan as “Acceptable” at “1 in 200,000 People”
To read the full story
Related Article
- Pfizer Japan to Discontinue Amoxapine after Carcinogen Issue
February 20, 2025
- Pfizer Japan Begins Amoxapine Recall, Ceases Shipments over Carcinogen Risks
February 27, 2023
- Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
- Nitrosamine Impurity Detected in Sitagliptin, Shipments in Japan to Continue with FDA-Set Limit: MSD/Ono
September 2, 2022
- Pfizer Japan to Curb Shipments and Recall Amoxapine over Carcinogen Risks
September 1, 2022
REGULATORY
- CAR-T Therapies Subject to Label Revision over Lymphoid Neoplasm Risk
March 6, 2025
- Safety-Related Label Revision Ordered for Trulicity, CP Inhibitors, and More
March 6, 2025
- Japan’s FY2025 Draft Budget Clears Lower House
March 5, 2025
- Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
March 4, 2025
- No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
March 3, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…